Partner
Chartered Patent Attorney
European Patent Attorney
UK Design Attorney
MA Natural Sciences, University of Cambridge
PhD Biochemistry, University of Bristol
Post-Doctoral Scientist, MRC-LMB and Gendaq Ltd
Thank you
Mike has a broad academic background in chemistry, medicinal chemistry, biochemistry, molecular biology and cellular biology, which experience was greatly enhanced during nine years of cutting-edge research in fields of biochemistry and molecular biology. He has authored many peer-reviewed publications and is an inventor of many patents.
Before entering the patent profession, Mike spent two years at a highly successful start-up / spin-out biotechnology and gene therapy company. This experience taught him the importance of developing a strong and commercially relevant intellectual property (IP) portfolio, especially to early stage companies.
Mike has a depth of experience in contentious matters and particularly enjoys the advocacy of EPO Opposition and Appeal proceedings. Complementing such contentious matters, a significant proportion of Mike’s work relates to freedom to operate and due diligence projects, especially in relation to fund raising and IPOs. In addition, he advises multinational corporations on their global patent strategy and handles all related prosecution advice in multiple jurisdictions. Mike also has an active registered design practice and advises small and multinational clients on issues of freedom to operate and infringement of registered and unregistered designs.
Mike works across a broad range of technology disciplines, spanning biotechnology to engineering, including specialisms in gene therapy and gene regulation, protein-DNA binding interactions, AI-driven chemistry and biology, agritech, automated guidance and control systems, automotive engineering, medical and diagnostic devices, pharmaceuticals and petrochemicals.
Mike joined Keltie in 2006 having spent over three years with another top-tier London firm of patent and trade mark attorneys. He qualified as a Chartered Patent Attorney in 2006 and as a European Patent Attorney in 2008. He became a Partner at Keltie in 2014.
Looking back, in 1993 Mike graduated from the University of Cambridge with an honours degree in Natural Sciences, specialising in chemistry and biochemistry. He then moved to the University of Bristol, where he completed a PhD in Biochemistry. During his time at Bristol he was awarded first prize at an International conference for his research in engineering of the structure and function of bacterial proteins. Mike then moved to the renowned MRC Laboratory of Molecular Biology in Cambridge, where he carried out four years of research into DNA-binding proteins and gene regulation under the guidance of Nobel Laureate Professor Sir Aaron Klug, O.M. He spent two years at a start-up biotechnology company, Gendaq Ltd, where he combined the roles of Senior Scientist and Internal Patent Coordinator before entering the patent profession.
Mike has also been recognised in Legal 500 2024 edition.
19.06.2024
Q&A with Michael Moore: Leading innovations in biotechnology and intellectual propertyKeltie features again in the Financial Times' prestigious list of Europe's Leading Patent Law Firms 2024. Keltie is one of the leading firms of IP specialists in Europe and is recognised by its peers across several core areas. We talk to Mike to discover what makes a successful IP firm and how biotechnology is evolving. He discusses his journey into the field and talks about all things ‘AI’.
30.04.2024
SMEs and Patents: Unlocking Innovation and Economic GrowthIntellectual property (IP) plays a pivotal role in driving innovation, fostering economic growth, and securing the competitive edge for companies. In the United Kingdom, IP intensive industries account for more than a quarter of the country’s output – around £300 billion a year – while intangible assets, including IP, may make up around 70 to 80% of a company’s overall value [1]. However, SMEs face unique challenges and opportunities when it comes to the realm of IP. In this article, Nathaniel Taylor sheds light on how SMEs (small and medium-sized enterprises) can mitigate cost issues to capitalise on their IP.
13.12.2022
Women and IP: a continuing journeyOtherLess related knowledge
Thank you
